MVXONCO-1 is under clinical development by MaxiVAX and currently in Phase I for Chordoma. According to GlobalData, Phase I drugs for Chordoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MVXONCO-1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MVXONCO-1 is under development for the treatment of lung carcinoma (either small cell or non-small cell), colon, breast, pancreas (exocrine or endocrine), stomach, oesophagus, head and neck squamous cell carcinoma, thyroid, kidney, bladder, prostate, ovary, uterus (cervix or corpus), sarcoma of soft tissue, bone, uterus, melanoma, chordoma, oral cavity cancer, pharyngeal cancer, laryngeal cancer and primary brain tumor. The drug candidate is a personalized vaccine administered subcutaneously as injections and capsules implantations. The drug candidate is a combination of two components, MVX-1-loaded microcapsules and irradiated autologous tumor cells.
MaxiVAX is a clinical stage biotechnology company that develops active immunotherapy with encapsulated cells for the treatment of cancer. Its lead product candidate includes MVX-ONCO-1, an immuno-oncology therapeutic vaccination that activates the patient’s own natural immune response mechanism through an innovative and proprietary technology in order to eliminate the deadly cancer cells. Its MVX-ONCO-1 consists of a small device and is placed underneath the skin. MaxiVAX’s product is composed of irradiated tumour cells of the patient and an immune-boosting agent, released from an encapsulated, cells being protected by the capsule from elimination by the patient’s immune response, thus produce locally the substance of interest locally for several weeks, genetically modified cell line. The company also conducts Phase 2 clinical study for the treatment of head and neck cancer, and several solid tumors. MaxiVAX is headquartered in Geneva, Switzerland.
For a complete picture of MVXONCO-1’s drug-specific PTSR and LoA scores, buy the report here.